Rula A Hajj-Ali Selected Research

Primary angiitis of the central nervous system

1/2019	Exploratory proteomic analysis implicates the alternative complement cascade in primary CNS vasculitis.
1/2018	CNS Vasculitis: an Approach to Differential Diagnosis and Management.
5/2007	Primary angiitis of the central nervous system.
12/2002	Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rula A Hajj-Ali Research Topics

Disease

4	Primary angiitis of the central nervous system 01/2019 - 12/2002
3	Vasculitis (Vasculitides) 11/2021 - 12/2016
2	Leukoencephalopathies 07/2021 - 11/2016
1	Demyelinating Diseases (Demyelinating Disease) 07/2021
1	Inflammation (Inflammations) 01/2021
1	Uveitis 01/2021
1	Central Nervous System Vasculitis 01/2019
1	Giant Cell Arteritis (Horton Disease) 02/2018
1	Meningitis 01/2018
1	Leukocytosis (Pleocytosis) 01/2018
1	Neuroinflammatory Diseases 01/2018
1	Atherosclerosis 10/2015
1	Systemic Vasculitis 01/2014
1	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2014
1	Polymyositis 01/2014
1	Dermatomyositis (Dermatopolymyositis) 01/2014
1	Migraine Disorders (Migraine) 08/2011
1	Mononeuropathies (Mononeuritis Multiplex) 01/2008
1	Headache (Headaches) 12/2002

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2018
3	GlucocorticoidsIBA 01/2018 - 05/2007
2	Retinaldehyde (Retinal)IBA 07/2021 - 11/2016
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 12/2016 - 01/2014
1	RA 25IBA 11/2021
1	Biosimilar PharmaceuticalsIBA 01/2021
1	Infliximab (Remicade)FDA Link 01/2021
1	ProperdinIBA 01/2019
1	Carrier Proteins (Binding Protein)IBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	Complement C5 (Complement 5)IBA 01/2019
1	Complement C8 (C8 Complement)IBA 01/2019
1	Complement C9 (Complement Component 9)IBA 01/2019
1	ProteomeIBA 01/2019
1	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 01/2019
1	S100 Proteins (S 100 Protein)IBA 10/2018
1	tocilizumab (atlizumab)FDA Link 02/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Indicators and Reagents (Reagents)IBA 01/2018
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018
1	NucleotidesIBA 01/2018
1	Intravenous Immunoglobulins (IVIG)FDA Link 12/2016
1	Pharmaceutical PreparationsIBA 08/2011
1	Etanercept (Enbrel)FDA Link 01/2008

Therapy/Procedure

2	Therapeutics 01/2018 - 05/2007
1	Aftercare (After-Treatment) 12/2002